Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

April 7, 2021

FDA green-lights human testing for Yale spinout’s COVID drug

IMAGE | Pixabay.com
By Natalie Missakian

A Branford pharmaceutical company spun out of Yale that is developing treatments for injured lungs has secured regulatory approval to start human testing on a drug for severe COVID-19.

Qx Therapeutics Inc. said it will begin enrolling patients in a Phase 2 clinical trial as early as next month after receiving a “safe to proceed” letter from the Food and Drug Administration.

Dubbed QXT-101, the drug aims to treat acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19, by inhibiting the MAP3K2/3 genes, the company said. 

Studies in mice have shown that inhibiting MAP2K2/3 protected them from developing ARDS, the company said.

The drug is based on technology discovered in Dr. Dianqing (Dan) Wu’s research laboratory at Yale. Founded in 2017, the company is based at 23 Business Park. 

The Phase 2 trial will test the safety and efficacy of the drug in hospitalized patients with severe or critical COVID-19, the company said. 

Contact Natalie Missakian at news@newhavenbiz.com

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF